Keep persistent efficacy by Abstaining from biological treatment after Numerical SDAI remission with AdalImumab (KANSAI study)
Latest Information Update: 12 May 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms KANSAI
- 21 Aug 2013 New trial record